Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 4/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | SELL | P14151 | 1/20 | 0.32 |
| ▸ | SELP | P16109 | 1/20 | 0.32 |
| ▸ | SELE | P16581 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | HCK | P08631 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14032881 | 0.88 | ERN1 (0.38) | ERN1NFE2L2CYP2A6ALDH1A1CA1 | |
| SCHEMBL15543777 | 0.84 | ALDH1A1 (0.37) | ERN1NFE2L2ALDH1A1MAPTRAPGEF4 | |
| SCHEMBL16207565 | 0.84 | ERN1 (0.34) | ERN1NFE2L2ALDH1A1PRKDCCYP3A4 | |
| SCHEMBL12581672 | 0.84 | SELL (0.46) | ERN1ALDH1A1SELLSELPSELE | |
| SCHEMBL16904919 | 0.81 | KDM4E (0.35) | ERN1ALDH1A1 | |
| SCHEMBL13083660 | 0.78 | PTGS2 (0.43) | ERN1NFE2L2CYP2A6ALDH1A1MAPT | |
| SCHEMBL95723 | 0.78 | ERN1 (0.50) | ERN1ALDH1A1SRCCA1PIK3CD | |
| SCHEMBL22418158 | 0.77 | ALDH1A1 (0.37) | ERN1NFE2L2ALDH1A1MAPT | |
| SCHEMBL1811153 | 0.76 | ALDH1A1 (0.39) | ERN1CYP2A6ALDH1A1 | |
| SCHEMBL1349783 | 0.74 | ERN1 (0.41) | ERN1ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105143445-B | Maturation of hepatocyte-like cells derived from human pluripotent stem cells | 宝生物欧洲公司 | 2020-07-07 | — | — | CN | claimed |
| US-20250109148-A1 | HETEROCYCLIC GLP-1 AGONISTS | SHANGHAI SHOUTI BIOTECHNOLOGY CO., LTD. (CN) | 2025-04-03 | — | — | US | disclosed |
| CN-119343339-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2025-01-21 | — | — | CN | disclosed |
| EP-4469444-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2024148280-A1 | TREATMENT OF ER+ BREAST CANCER COMPRISING HOMOLOGOUS RECOMBINATION DEFICIENCY USING PARC INHIBITOR | IDEAYA BIOSCIENCES, INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| WO-2023138684-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO , INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-105143445-B | Maturation of hepatocyte-like cells derived from human pluripotent stem cells | 宝生物欧洲公司 | 2020-07-07 | — | — | CN | disclosed |
| US-10647724-B2 | Selective estrogen receptor degraders and uses thereof | INVENTISBIO INC. (KY) | 2020-05-12 | — | — | US | disclosed |
| US-20200040001-A1 | SELECTIVE ESTROGEN RECEPTOR DEGRADERS AND USES THEREOF | INVENTISBIO LLC | 2020-02-06 | — | — | US | disclosed |
| WO-2010129208-A1 | P38 KINASE INHIBITING AGENTS | MERCK SHARP & DOHME CORP. (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010129208-A1 | P38 KINASE INHIBITING AGENTS | MERCK SHARP & DOHME CORP. (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20090325953-A1 | P38 KINASE INHIBITING AGENTS | MERCK SHARP & DOHME LLC | 2009-12-31 | — | — | US | disclosed |
| US-20090325953-A1 | P38 KINASE INHIBITING AGENTS | MERCK SHARP & DOHME LLC | 2009-12-31 | — | — | US | disclosed |
| US-20090325953-A1 | P38 KINASE INHIBITING AGENTS | MERCK SHARP & DOHME LLC | 2009-12-31 | — | — | US | disclosed |
| WO-2009152072-A1 | PYRROLO [2, 3-C] PYRIDINE DERIVATIVES AS P38 KINASE INHIBITING AGENTS | MERCK & CO., INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009152072-A1 | PYRROLO [2, 3-C] PYRIDINE DERIVATIVES AS P38 KINASE INHIBITING AGENTS | MERCK & CO., INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| US-20090131457-A1 | Pyrazolo [3,4-D] Pyrimidine Derivatives Useful to Treat Respiratory Disorders | NOVARTIS AG (CH) | 2009-05-21 | — | — | US | disclosed |
| US-20090131457-A1 | Pyrazolo [3,4-D] Pyrimidine Derivatives Useful to Treat Respiratory Disorders | NOVARTIS AG (CH) | 2009-05-21 | — | — | US | disclosed |
| WO-2007134828-A1 | PYRAZOLO [3, 4-D] PYRIMIDINE DERIVATIVES USEFUL TO TREAT RESPIRATORY DISORDERS | NOVARTIS AG (CH) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131457-A1 | Pyrazolo [3,4-D] Pyrimidine Derivatives Useful to Treat Respiratory Disorders | PIK3CA, JAK3, PDK1 | ERN1 518/4885NFE2L2 4398/4885CYP2A6 1483/4885 |
| US-20250109148-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | ERN1 2681/4885NFE2L2 3488/4885CYP2A6 2118/4885 |
| US-20090325953-A1 | P38 KINASE INHIBITING AGENTS | MAPK1, MAPK8, MAPKAPK2 | ERN1 626/4885NFE2L2 1369/4885CYP2A6 2589/4885 |
| US-10647724-B2 | Selective estrogen receptor degraders and uses thereof | ESR1, ESRRA, ESR2 | ERN1 1805/4885NFE2L2 412/4885CYP2A6 74/4885 |
| US-20200040001-A1 | SELECTIVE ESTROGEN RECEPTOR DEGRADERS AND USES THEREOF | ESR1, ESRRA, ESR2 | ERN1 1805/4885NFE2L2 412/4885CYP2A6 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.